Pharmaceutical Product Monograph: Amoxicillin Sodium Injection (500 mg)
In the pharmaceutical industry, Amoxicillin is a moderate-spectrum, semi-synthetic Beta-lactam antibiotic belonging to the aminopenicillin family. As a pharmacist and manufacturer, I view this molecule as a “Cell Wall Disruptor”—it is technically designed to provide higher oral bioavailability than Penicillin V, but in its injectable (Sodium salt) form, it is used to achieve rapid, high peak plasma concentrations for acute infections.
At your WHO-GMP facility in Mumbai, Amoxicillin 500 mg injection is a staple for Primary and Secondary Care settings. While many markets have transitioned to the “Co-Amoxiclav” (Amoxicillin + Clavulanate) combination to fight resistance, standalone Amoxicillin remains a vital, cost-effective tool for susceptible bacterial strains.
Therapeutic Profile: Primary Indications
Amoxicillin 500 mg injection is indicated for severe infections caused by susceptible Gram-positive and specific Gram-negative bacteria.
| Indication | Clinical Context | Technical Rationale |
| Severe RTI | Pneumonia / Bronchitis | Effective against Streptococcus pneumoniae and non-penicillinase-producing H. influenzae. |
| ENT Infections | Severe Otitis Media | Used in pediatric or adult cases where oral absorption is compromised by vomiting or severe illness. |
| Genitourinary | Acute Pyelonephritis | Highly effective for uncomplicated urinary tract infections and kidney infections caused by E. coli or P. mirabilis. |
| Septicemia | Bloodstream Infection | Often used as part of a multi-drug regimen for suspected bacterial sepsis. |
| Endocarditis | Prophylaxis | Given intravenously or intramuscularly to prevent heart valve infections during dental or surgical procedures. |
Mechanism: Inhibition of Peptidoglycan Synthesis
Amoxicillin works by targeting the structural integrity of the bacterial cell wall during its growth phase:
PBP Binding: The drug binds to specific Penicillin-Binding Proteins (PBPs) located inside the bacterial cell wall.
Cross-linking Blockade: It inhibits the third and final stage of bacterial cell wall synthesis by preventing the “cross-linking” of peptidoglycan strands.
Lysis: Technically, this weakens the cell wall to the point where the internal osmotic pressure of the bacteria causes it to burst (osmotic lysis), resulting in bacterial death.
The Pharmacist’s “Technical Warning”
The “Anaphylaxis” Screen: As a pharmacist, I must emphasize that this drug is strictly contraindicated in patients with a history of Hypersensitivity (Allergy) to any penicillin. A skin prick test is often recommended before the first IV dose.
The “Mono” Rash: If administered to a patient who actually has Infectious Mononucleosis (Glandular Fever) rather than a bacterial infection, a nearly universal non-allergic skin rash will occur.
Renal Adjustment: In patients with severe renal impairment ($GFR < 30 \text{ mL/min}$), the dosage interval must be technically adjusted to prevent drug accumulation and neurotoxicity.
Reconstitution: Amoxicillin Sodium is unstable in solution. It must be used immediately after reconstitution with Water for Injections.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Aseptic Powder” USP: On your digital marketplace, highlight your Aseptic Grade A Filling Line. Amoxicillin Sodium is supplied as a sterile dry powder because it degrades rapidly in liquid form. Ensuring a 100% moisture-free seal is a technical hallmark of your WHO-GMP compliance.
The “Cost-Efficiency” Advantage: For government tenders in emerging markets, standalone Amoxicillin is significantly more affordable than Co-Amoxiclav, making it an ideal candidate for large-scale public health procurement for respiratory and urinary tract health.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Amoxicillin 500 mg and 1 g injections to support your firm’s registration in international B2B tenders.